Q1 2027 Aarti Drugs Ltd Earnings Call Transcript
Key Points
- Aarti Drugs Ltd (BOM:524348) reported a strong 19% YoY revenue growth and a 30% YoY increase in EBITDA for Q1 FY27, with EBITDA margin expanding by 120 basis points to 13.8%.
- The company benefited from a favorable pricing environment across several API products, leading to significantly better realizations, particularly for metformin, which saw a 15-20% price increase.
- Operational resilience was demonstrated with no production disruptions or material shortages, ensuring stable operations and timely customer deliveries despite geopolitical challenges.
- The Saykha facility reached nearly 65% utilization, contributing to improved operational efficiency and supporting backward integration, especially for the anti-diabetic segment.
- The company is strategically expanding its regulated market presence, with plans to scale up metformin capacity to 2,200 tons per month, including a US FDA-approved block, and has already secured approvals for nine products in Europe.
- The specialty chemicals segment showed robust growth, with sales up 149% YoY, driven by the Saykha facility, and management expects this performance to continue for the rest of the year.
- The ongoing geopolitical conflict in West Asia has led to elevated freight costs, longer procurement cycles, and increased volatility in raw material pricing, which could pressure margins.
- The salicylic acid plant at Tarapur continues to face challenges, with production kept very low (67 tons in Q1) and the anti-dumping duty case delayed by at least a year, impacting profitability.
- The company's volume growth was modest at 3.5% YoY, with most of the revenue growth driven by price increases, which may not be sustainable once geopolitical tensions ease.
- The US FDA approval for the new metformin capacity is expected to take at least 12 months, delaying potential revenue from the US market.
- The company had to take write-offs of aging CWIP in Q1, which impacted EBITDA margins, and the full benefit of backward integration at Saykha is still pending, with only 60-70% of intermediates procured externally.
- The pricing environment remains volatile, and if raw material prices decline, selling prices may also drop, potentially affecting future revenue and margin growth.
Ladies and gentlemen, good day, and welcome to Q1 FY27 earnings conference call of Aarti Drugs Limited. (Operator Instructions)
Before we begin, a brief disclaimer. This conference call contain forward-looking statements about the company, which are based on the beliefs, opinions, and expectations of the company as of the date of this call. These statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict.
I now have the conference over to Mr. Adhish Patil, COO and CFO from Aarti Drugs Limited. Thank you, and over to you, Mr. Patil.
Good morning, everyone. Thank you for joining us today for Aarti Drugs' Q1 FY27 earnings discussion. Joining me today are Mr. Harshit Savla, Joint Managing Director.
Good morning.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
